66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03188887 (ClinicalTrials.gov) | February 20, 2018 | 2/5/2017 | Treatment of IgA Nephropathy According to Renal Lesions | Treatment of IgA Nephropathy According to Renal Lesions | IgA Nephropathy | Drug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockade | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | N/A | All | 122 | Phase 3 | France |
| 2 | NCT03015974 (ClinicalTrials.gov) | January 2016 | 3/1/2017 | Registry of IgA Nephropathy in Chinese Children | Registry of IgA Nephropathy in Chinese Children | IgA Nephropathy;Proteinuria in Nephrotic Range;Immunosuppressive Treatment | Drug: Corticosteroid;Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Dipyridamole;Drug: ACE Inhibitor or Angiotensin receptor antagonist | Peking University First Hospital | Nanjing PLA General Hospital;Beijing Children's Hospital;Central South University;The Children's Hospital of Zhejiang University School of Medicine;First Affiliated Hospital, Sun Yat-Sen University;Tongji Hospital;Hunan Children's Hospital;Shanghai Children's Hospital;Nanjing Children's Hospital;Children's Hospital of Chongqing Medical University;Shandong Provincial Hospital;Fuzhou General Hospital;Second Affiliated Hospital of Wenzhou Medical University;Children's Hospital of Hebei Province;Guangzhou Women and Children's Medical Center;Jiangxi Province Children's Hospital;Guangzhou First People's Hospital;Xian Children's Hospital;Capital Institute of Pediatrics, China;First Hospital of Jilin University;Wuhan Women and Children's Medical Center;Tianjin Children's Hospital;Chengdu Women's and Children's Central Hospital;The First People's Hospital of Yunnan | Recruiting | 1 Month | 18 Years | All | 1200 | China | |
| 3 | NCT01237028 (ClinicalTrials.gov) | March 2011 | 8/11/2010 | Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers | Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers | IgA Nephropathy | Drug: Calcitriol | Yonsei University | NULL | Completed | 20 Years | 70 Years | Both | 168 | N/A | Korea, Republic of |
| 4 | NCT00922311 (ClinicalTrials.gov) | July 2009 | 14/6/2009 | Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade | Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study | IgA Nephropathy | Drug: Aliskiren | The University of Hong Kong | Queen Mary Hospital, Hong Kong;United Christian Hospital | Completed | 18 Years | 70 Years | Both | 25 | Phase 4 | China |
| 5 | EUCTR2005-003885-40-IT (EUCTR) | 18/10/2005 | 15/01/2007 | ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria - | The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders | Product Name: Ramipril INN or Proposed INN: Ramipril Product Name: Irbesartan INN or Proposed INN: Irbesartan | AZIENDA OSPEDALIERA PROVINCIALE DI LECCO | NULL | Not Recruiting | Female: yes Male: yes | Italy | |||||
| 6 | JPRN-C000000341 | 2004/04/01 | 31/03/2006 | Randomised controlled trial of multiple drugs combined therapy for diffuse IgA nephropathy | Refractory IgA nephropathy | Prednisolone and anti-thrombocyte and angiotensin II receptor blocker or angiotensin converting enzyme inhibitor inhibitor mizoribine and Prednisolone and anti thrombocyte and angiotensin II receptor blocker or angiotensin-converting enzyme | Japanese Study Group of Multiple drug therapy for IgAN | NULL | Complete: follow-up complete | 16years-old | 75years-old | Male and Female | 60 | Not selected | Japan | |
| 7 | ChiCTR-TRC-09000630 | 2004-01-01 | 2005-09-06 | Treatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled Trial | Treatment of Early Immunoglobulin A Nephropathy by the Angiotensin Converting Enzyme Inhibitor Ramipril - A Randomized Controlled Trial | IgA nephropathy | Two groups:ramipril 5 years versus no treatment; | The Chinese University of Hong Kong | NULL | Recruiting | 0 | 0 | Male | Two groups:60; | China | |
| 8 | NCT01225445 (ClinicalTrials.gov) | April 2002 | 20/10/2010 | Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial | Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial | Biopsy-confirmed IgA Nephropathy;Proteinuria Less Than 0.5 g Per Day;Normal Blood Pressure;Serum Creatinine Below 120 Umol/l | Drug: Ramipril | Chinese University of Hong Kong | NULL | Completed | 18 Years | 25 Years | Both | 60 | Phase 3 | Hong Kong |
| 9 | NCT00863252 (ClinicalTrials.gov) | March 2002 | 15/3/2009 | Mycophenolate Mofetil for IgA Nephropathy | A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade | IGA Nephropathy | Drug: mycophenolate mofetil;Drug: angiotensin blockade | The University of Hong Kong | United Christian Hospital;Queen Mary Hospital, Hong Kong | Completed | 18 Years | 70 Years | Both | 40 | Phase 4 | China |
| 10 | NCT00367562 (ClinicalTrials.gov) | January 1996 | 22/8/2006 | Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy | Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy | IGA Nephropathy | Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE | Hospital Britanico | NULL | Completed | 21 Years | 70 Years | Both | 20 | Phase 4 | Argentina |